CD19-redirected Autologous Cells (CAR-CD19 T Cells)

NCT02933775 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

CD19 Positive Malignant B-cell Leukemia and Lymphoma

Interventions

GENETIC: CAR-CD19 T cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

RenJi Hospital

Collaborators

[object Object]